Helix Biopharma (OTCMKTS:HBPCF) Posts Earnings Results

by · The Cerbat Gem

Helix Biopharma (OTCMKTS:HBPCF – Get Free Report) announced its earnings results on Friday. The company reported ($0.01) earnings per share (EPS) for the quarter, Zacks reports.

Helix Biopharma Stock Performance

OTCMKTS HBPCF remained flat at $1.73 during trading hours on Friday. The company has a market capitalization of $132.43 million, a PE ratio of -24.77 and a beta of 0.17. Helix Biopharma has a one year low of $0.59 and a one year high of $1.73. The firm has a fifty day moving average of $1.44 and a 200 day moving average of $0.89.

Helix Biopharma Company Profile

(Get Free Report)

Helix BioPharma Corp. operates as an immune-oncology company in Canada. It is developing L-DOS47 for the treatment of non-small cell lung cancer; and V-DOS47 that targets the vascular epithelial growth factor receptor 2. Helix BioPharma Corp. has collaboration agreements with Moffitt Cancer Center to investigate the pharmacodynamics of L-DOS47 and determine the benefits of combining L-DOS47 with immune checkpoint inhibitors; and with University Hospital Tuebingen to assess the therapeutic response of L-DOS47 in cancer models expressing CEACAM6, with advanced preclinical metabolic imaging.

Featured Stories